Dr. Bumpers is Professor of Surgery and Director of the Breast surgery at MSU, CHM. He is a Board Certified surgeon, surgical oncologist and breast specialist. He graduated from The University of Rochester School of Medicine in Rochester, New York with a M.D with Distinction in Research. He completed General Surgery residency at Stony Brook University School of Medicine in Long Island, N.Y. During the surgery residency he added 2 years of basic science research in Surgical Oncology. He then went on to complete a clinical Surgical Oncology Fellowship at Roswell Park Cancer Institute in Buffalo, N.Y. He joined the faculty at University of Buffalo in New York as Assistant Professor from 1991-1996. Afterward he joined Morehouse School of Medicine in Atlanta, GA as Associate Professor and rose to the rank of Professor. In 2011 he joined MSU to head Breast Surgery. Dr. Bumpers has a dedication to community outreach regarding breast cancer and he has done workshops for the community every year since 1988. For the past 25 years he has also been committed to laboratory research in cellular biology and animal cancer modeling with breast and colon cancers. This research has continued at MSU with breast cancer carcinogenesis, metastasis and development of animal models.

Dean Shinabarger received a B.S. in Biology from Emporia State University in 1982, and a Ph.D. in Microbiology from Louisiana State University in 1986. He was a postdoctoral fellow in the laboratory of Dr. Leo Parks at North Carolina State University from 1986-88, studying sterol synthesis in yeast. In addition, he completed a second fellowship from 1989-91 at the University of Illinois College of Medicine in Chicago under Dr. Ananda Chakrabarty, investigating the molecular biology and enzymology of Pseudomonas aeruginosa alginate synthesis as related to cystic fibrosis patient lung infections. Dr. Shinabarger began his industrial career at Proctor & Gamble Pharmaceuticals in 1992 in the anti-infective discovery program. After 2 years, he moved to Upjohn Pharmaceuticals in 1994 to join the discovery and development team working on the oxazolidinone class of antibacterial agents. Dr. Shinabarger’s lab elucidated the mechanism of action/resistance of Gram-positive bacteria to linezolid, and he was a member of the team that presented Zyvox successfully to the FDA advisory committee, resulting in its approval. Dr Shinabarger exited a few months after Pfizer acquired Pharmacia, and in 2004 cofounded Micromyx, a microbiology services company that conducts antibacterial and antifungal R&D. After 15 years as CEO, Dr. Shinabarger successfully negotiated the sale of Micromyx to Microbiologics in September 2019. He currently serves as an antimicrobial consultant for biotech and pharma companies.

20+ years of research and program leadership experience with advanced expertise in virology, vaccinology, immunology and protein sciences. As an Assistant Professor of Medicine / Virology at Harvard Medical School, conducted discovery research focusing on vaccine design to HIV/AIDS. As Director, Vaccine Technology at Pfizer, Vaccine R&D, served as the Program Lead for the anti-HCMV vaccine program, performing innovative research and providing strategic and scientific leadership with global experience leading cross-functional teams.

Received a medical education and master’s degree on epidemiology at Shanghai Medical University (Now Fudan University Medical School, Shanghai, China) and awarded a PhD degree on virology at Baylor College of Medicine (Houston, TX). Over the years, published over 40 original research papers and produced 11 patent applications.